The purchase price, which is confidential & was negotiated for a total of 300 million doses, is somewhat less than the $19.50 a photo the United States agreed to purchase a first shipment of hundred million doses of the same vaccine, in line with what Reuters reported in November.
The EU document dated Nov. eighteen was circulated internally following the EU announced its supply offer with Pfizer and its German partner BioNTech on Nov. 11.
The EU drug regulator is expected to determine on Monday on acceptance for the Pfizer vaccine following the photo was authorised in a number of countries, including Britain as well as the United States.
On Thursday Belgian say secretary for the budget Eva De Bleeker published on Twitter a dining room table with prices Belgium will pay pharmaceutical companies for the COVID-19 vaccines of theirs. She retracted the article shortly after posting.
In that dinner table the Pfizer vaccine was indicated as costing Belgium twelve euros ($14.6) per dose, top many to believe this was the total price agreed by the EU.
Various other vaccines in the table were also shown with rates lower compared to rates disclosed by EU sources.
“There is for sure a complete fee and a cost after delivery,” an EU official involved in talks with vaccine creators told Reuters when directed to clarify the difference between the EU and Belgian rates.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality requirements, but pointed to what De Bleeker told the Belgian parliament previous week. In that public hearing, De Beeker stated Belgium’s budgeted prices were still partial.
Under EU advance purchase deals for COVID 19 vaccines, the bloc agrees upfront payments with companies to secure doses before they’re approved. After approvals, EU governments can pay the rest to buy reserved doses.
The EU has not revealed the upfront transaction agreed with Pfizer.
However, it said in October that it paid about one billion euros inside downpayments to AstraZeneca, Sanofi and Johnson & Johnson for their shots, with a further 1.45 billion euros budgeted for initial payments to Pfizer-BioNTech, Curevac and Moderna.
It has since agreed supply deals with all six companies and is negotiating a seventh agreement with Novavax.